Early detection

The fastest and most accurate way to diagnose basal cell, squamous cell and melanoma cancers

Most skin cancers – especially melanoma and squamous cell carcinoma – present higher risks when left untreated for extended periods. However, skin cancer diagnosis is a time-consuming process that almost always takes a week to confirm. Thanks to the development of Spectra- Scope, a nearly instantaneous skin cancer diagnosis is now workable.

Spectra-Scope is a portable device that detects the biochemical information of skin tissue using laser-induced plasma spectroscopy (LIPS). It comes with a deeplearning AI-based diagnostic algorithm for fast and accurate oncological diagnosis.

Spectra-Scope’s LIPS technology uses a laser irradiation of a few nanoseconds to induce micro-plasma on the skin tissue without any tissue damage.

The micro-plasma emissions created by the laser instantly reveal the biochemical information of the skin tissue at the molecular and atomic level.

Each emission spectrum of skin tissue acquired using LIPS has over 4,000 parameters, providing detailed biochemical information of the tissue.

Spectra-Scope’s deep learningbased proprietary diagnostic algorithm differentiates the conditions of basal cell carcinoma, squamous cell carcinoma and malignant melanoma with accuracy.

The diagnostic algorithm was constructed by a deep neural network trained with over 7,254 emission spectra.

Spectra-Scope is quick, safe and easy to use. To evaluate the degree of atypia in a lesion, measurements are performed on a reference area close to the lesion, as well as on the lesion itself. The procedure takes only a second, and the LIPS score and corresponding clinical predictive value of the lesion are displayed within a few seconds.

Spectra-Scope’s diagnostic accuracy has been proven by worldwide clinical studies in the US and Australia. Spectra-Scope is also undergoing trails by leading skin cancer specialists in private and NHS sectors within the UK.

A deep learning-based algorithm was used to create a robust database of information, leading to ground-breaking accuracy in both sensitivity and specificity.

The identification of skin cancers (basal cell carcinoma, squamous cell carcinoma and malignant melanoma) vs. benign lesions were accurately diagnosed with 97.6% sensitivity and 86.2% specificity. 1

The LIPS score reflects the degree of atypia in a lesion and indicates the risk of skin lesion malignancy.

For each diagnostic result (LIPS score) generated, the corresponding negative predictive value (NPV) and positive predictive value (PPV) derived from the clinical study is also presented. These clinically meaningful parameters can help doctors and dermatologists obtain more information about the skin lesion and decide on the best course of action.

Spectra-Scope provides a platform to record a substantial amount of lesion information, including the location of the lesion, its LIPS score, and the corresponding predictive diagnostic values, as well as patient data.

Spectra-Scope has been successful for many years in Australia for diagnosing skin cancers in top medical centres and is currently licenced for medical use in the UK.

Cosmeditech is a leading supplier of medical and aesthetic laser devices in the UK, currently working to develop Spectra-Scope in UK private and NHS sectors.

For more information visit spectra-scope.co.uk